Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCHANTED trial in acute ischaemic stroke
ACTRN12611000236998Phase 4Completed
- Sponsor
- The George Institute for Global Health
- Start
- Mar 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator, clevidipine, labetalol, metoprolol, hydralazine and 2 more in brain infarction and hypertension (HTN) (4 arms), sponsored by The George Institute for Global Health. Primary endpoints: Death and any disability and Modified Rankin Scale ordinal shift. Started Mar 2012; status: completed.
02
Drugs
tissue-plasminogen activatorclevidipinelabetalolmetoprololhydralazine
03
Conditions
brain infarctionhypertension (HTN)
Beyond the preview
Go deeper on ACTRN12611000236998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000236998.